Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.


Results 71-80 of 183 (Search time: 0.005 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2008Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukemia?Hughes, T.
2014Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepointBranford, S.; Ross, D.; Yeung, D.; Braley, J.; Hughes, T.; 56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)
2010A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be AppropriateBranford, S.; Goh, H.; Izzo, B.; Beppu, L.; Ortmann, C.; Duniec, K.; Jin, Y.; Woodman, R.; Pane, F.; Kim, D.; Radich, J.; Hughes, T.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2017Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cellsWang, J.; Lu, L.; Kok, C.; Saunders, V.; Goyne, J.; Dang, P.; Leclercq, T.; Hughes, T.; White, D.
2017A method for next-generation sequencing of paired diagnostic and remission Samples to detect mitochondrial DNA mutations associated with leukemiaPagani, I.; Kok, C.; Saunders, V.; Van der Hoek, M.; Heatley, S.; Schwarer, A.; Hahn, C.; Hughes, T.; White, D.; Ross, D.
2012Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cellsWang, J.; Hughes, T.; Kok, C.; Saunders, V.; Frede, A.; Groot Obbink, K.; Osborn, M.; Somogyi, A.; D'Andrea, R.; White, D.
2017A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOHSadras, T.; Heatley, S.; Kok, C.; McClure, B.; Yeung, D.; Hughes, T.; Sutton, R.; Ziegler, D.; White, D.
2018Molecular monitoring in CML: How deep? How often? How should it influence therapy?Shanmuganathan, N.; Hughes, T.
2008Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: Implications for defining sensitivity in minimal residual diseaseRoss, D.; Watkins, D.; Hughes, T.; Branford, S.
2018Molecular monitoring in CML: how deep? How often? How should it influence therapy?Shanmuganathan, N.; Hughes, T.